Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 03

155P - Search for circulating tumor cells in patients with urothelial cancer

Date

03 Dec 2022

Session

Poster viewing 03

Topics

Laboratory Diagnostics;  Basic Science

Tumour Site

Urothelial Cancer

Presenters

Irina Kruglova

Citation

Annals of Oncology (2022) 33 (suppl_9): S1485-S1494. 10.1016/annonc/annonc1124

Authors

I.A. Kruglova1, S.V. Zinoviev2, O.V. Utkin3, A.N. Denisenco4

Author affiliations

  • 1 Clinacal Labjratory, City Hospital No.35, 603089 - Niznii Novgorod/RU
  • 2 Oncogynecology, Nizniy Novgorod regional oncology centre, 60300- - Nizniy Novgorod/RU
  • 3 Molecular Biology And Biothechnology, Nizniy Novgorod scientific Research Institute of Epidemiology and Microbiology, 60300 - Nizniy Novgorod/RU
  • 4 City Hospital, City Hospital No.35, 603089 - Niznii Novgorod/RU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 155P

Background

Circulating tumor cells (CTCs) are cells of epithelial origin from clones of the primary tumor, located in the G0 phase and found in the peripheral blood of patients with various forms of solid cancer. Currently, CTCs are found in breast cancer, prostate cancer, colorectal cancer, and their number is used as an independent prognostic factor. The detection of CTCs in various tumors can help in the study of the process of metastasis and the biology of tumor growth. The aim of the work is to establish the presence and frequency of CTCs in the peripheral blood of patients with cancer in the bladder.

Methods

41 peripheral blood samples from patients with verified bladder cancer of stage III-IV were analyzed. The blood was taken into vacuum tubes with anticoagulant. The selection of the CTC on the density gradient. From the obtained material, 2 cytological preparations were prepared on the cytocentrifuge of Hospitex diagnostics (Italy) and stained according to Romanovsky. Calculation of the CTC at the light-optical level using a Zeiss Primo Star microscope (Germany). The final result was the total number of detected CTCs. The control group consisted of peripheral blood samples from 10 patients without cancer.

Results

CTCs were detected in 46.3% of cases (19 samples) in the amount of 1-14 cells. In the morphological structure of primary tumors, according to the results of histological examination, the samples were divided as follows: squamous cell carcinoma – 1, adenocarcinoma (metastasis of cervical cancer) – 1, urothelial carcinoma – 17. The calculation of the CTC by morphological forms of the tumor showed that 4-6 cells were detected in squamous cell carcinoma, 6 cells in adenocarcinoma, and 2 - 14 cells in urothelial carcinoma (2-4 cells in the II st., 7-14 cells in the IIII st.; Xsr=2.43). In the blood samples of the control patients, CTCs were also not detected.

Conclusions

The presence of CTC in the peripheral blood of patients with bladder cancer was detected in 46.3% of cases and has differences depending on the morphological form of the tumor, which requires further study. The largest number of CTCs in our study was revealed in the transitional cell (urothelial) morphological form of cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.